A Phase 1/2 Study of IMGN632 in People with Blastic Plasmacytoid Dendritic Cell Neoplasm


Full Title

A Phase 1/2, Multicenter, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies


In this study, researchers are assessing the safety and effectiveness of the investigational drug IMGN632 in people with a blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) that makes a protein called CD123. This protein promotes cancer growth. IMGN632 works against cancer by targeting cancer cells containing CD123 and then delivering a cancer-killing drug. By targeting CD123-positive cancer cells, IMGN632 may cause cancer cells to stop growing and multiplying. It is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have BPDCN that came back or continued to grow despite no more than three prior regimens of treatment.
  • Patients’ cancers must make the CD123 protein.
  • At least 2 weeks must pass between the completion of previous therapies and receipt of IMGN632.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Raajit Rampal at 646-608-3746.





Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID